About: Protective immunity by an engineered DNA vaccine for Mayaro virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protective immunity by an engineered DNA vaccine for Mayaro virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Protective immunity by an engineered DNA vaccine for Mayaro virus
Creator	Choi, Hyeree Ho, Michelle Humeau, Laurent Ramos, Stephanie Reed, Charles Tebas, Pablo Weaver, Scott Aguilar, Patricia Bopp, Nathen Kim, J Reuschel, Emma Weiner, David Asijaid, Kanika Boroleid, Piyush Kudchodkarid, Sagar Muthumaniid, Kar Wojtakid, Krzysztof
Source	Medline; PMC
abstract	Mayaro virus (MAYV) of the genus alphavirus is a mosquito-transmitted emerging infectious disease that causes an acute febrile illness, rash, headaches, and nausea that may turn into incapacitating, persistent arthralgias in some victims. Since its discovery in Trinidad in 1954, cases of MAYV infection have largely been confined there and to the northern countries of South America, but recently, MAYV cases have been reported in some island nations in the Caribbean Sea. Accompanying these reports is evidence that new vectors, including Aedes spp. mosquitos, recently implicated in the global spread of Zika and chikungunya viruses, are competent for MAYV transmission, which, if true, could facilitate the spread of MAYV beyond its current range. Despite its status as an emerging virus, there are no licensed vaccines to prevent MAYV infection nor therapeutics to treat it. Here, we describe the development and testing of a novel DNA vaccine, scMAYV-E, that encodes a synthetically-designed consensus MAYV envelope sequence. In vivo electroporation-enhanced immunization of mice with this vaccine induced potent humoral responses including neutralizing antibodies as well as robust T-cell responses to multiple epitopes in the MAYV envelope. Importantly, these scMAYV-E-induced immune responses protected susceptible mice from morbidity and mortality following a MAYV challenge.
has issue date	2019-02-07(xsd:dateTime)
bibo:doi	10.1371/journal.pntd.0007042
bibo:pmid	30730897
has license	cc-by
sha1sum (hex)	a5a3e3edfad63f20fc48ba5885fb9cc863411d2e
schema:url	https://doi.org/10.1371/journal.pntd.0007042
resource representing a document's title	Protective immunity by an engineered DNA vaccine for Mayaro virus
has PubMed Central identifier	PMC6366747
has PubMed identifier	30730897
schema:publication	PLoS Negl Trop Dis
resource representing a document's body	covid:a5a3e3edfad63f20fc48ba5885fb9cc863411d2e#body_text
is schema:about of	named entity 'susceptible' named entity 'range' named entity 'potent' named entity 'NAUSEA' named entity 'MULTIPLE' covid:arg/a5a3e3edfad63f20fc48ba5885fb9cc863411d2e named entity 'RESPONSES' named entity 'PERSISTENT' named entity 'SUSCEPTIBLE' named entity 'LICENSED' named entity 'COUNTRIES' named entity 'VIRUSES' named entity 'DESCRIBE' named entity 'MICE' named entity 'RANGE' named entity 'SPP' named entity 'TRINIDAD' named entity 'CURRENT' named entity 'CASES' named entity 'SEQUENCE' named entity 'CHALLENGE' named entity 'FOLLOWING' named entity 'ARTHRALGIAS' named entity 'TRANSMITTED' named entity 'T-CELL' named entity 'SPREAD' named entity 'GLOBAL' named entity 'DNA VACCINE' named entity 'TURN' named entity 'MOSQUITOS' named entity 'PROTECTIVE IMMUNITY' named entity 'DNA VACCINE' named entity 'ENGINEERED' named entity 'VACCINE' named entity 'ACUTE FEBRILE ILLNESS' named entity 'TRUE' named entity 'RASH' named entity 'IS A' named entity 'SOUTH AMERICA' named entity 'BUT' named entity 'CONSENSUS' named entity 'CARIBBEAN SEA' named entity 'ACCOMPANYING' named entity 'MOSQUITO' named entity 'DEVELOPMENT' named entity 'VICTIMS' named entity 'ENVELOPE' named entity 'THESE' named entity 'CAUSES' named entity 'HEADACHES' named entity 'VACCINES' named entity 'ENHANCED' named entity 'DISCOVERY' named entity 'TO PREVENT' named entity 'IMMUNIZATION' named entity 'ELECTROPORATION' named entity 'IMMUNE RESPONSES' named entity 'AEDES' named entity 'MAYARO VIRUS' named entity 'BEYOND' named entity 'ZIKA' named entity 'RECENTLY' named entity 'THERAPEUTICS' named entity 'EPITOPES' named entity 'TREAT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software